A phase 1 clinical trial of OB-002H
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs OB 002H (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 29 Jan 2019 According to an Orion Biotechnology media release, the company plans to submit a regulatory filing in Q1 2019 to support initiation of this study in Q3 2019.
- 09 Nov 2018 New trial record
- 31 Oct 2018 According to an Orion Biotechnology media release,clinical study design was appropriate and met MHRA requirements. Company is preparing for clinical trial application (CTA) to be submitted and looking forward to receive feedback from the Polish National Regulatory authority.